Recombinant factor VIIa. An update on its clinical use

Thrombosis and Haemostasis

Volumn 93, Issue 6, 2005, Pages 1027-1035

  Franchini, Massimo ^a   Zaffanello, Marco ^b   Veneri, Dino ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Bleeding; Haemophilia; Inhibitors; Recombinant FVIIa

Indexed keywords

ANTIFIBRINOLYTIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TRANEXAMIC ACID; VITAMIN K GROUP; WARFARIN;

BLEEDING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; GLANZMANN DISEASE; HEART INFARCTION; HEMOPHILIA; HUMAN; LIVER DISEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION DISORDERS; BLOOD PLATELET DISORDERS; FACTOR VIIA; HEMOPHILIA A; HEMORRHAGIC DISORDERS; HEMOSTASIS, SURGICAL; HUMANS; LIVER DISEASES; RECOMBINANT PROTEINS; WOUNDS AND INJURIES;

EID: 20444452505     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-01-0032     Document Type: Review

References (172)

1. Lusher J, Ingerslev J, Roberts H et al. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 9: 119-28.
2. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19: 163-76.
3. Nègrier C, Lienhart A. Overall experience with Novoseven®. Blood Coagul Fibrinolysis 2000; 11(suppl 1): 19-24.
4. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7: 408-13.
5. Jurlander B, Thim L, Klausen NK et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing and clinical development. Semin Thromb Hemost 2001; 27: 373-83.
6. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42: 114-24.
7. Uhlmann EJ, Eby CS. Recombinant activated factor VIII for non-hemophiliac bleeding patients. Curr Opin Hematol 2004; 11: 198-204.
8. Goodnough LT, Lublin DM, Zhang L et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44: 1325-31.
9. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev 2004; 18: 245-59.
10. Mathew P. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. Thromb Haemost 2004; 92: 738-46.
11. Hedner U. Recombinant factor VIIa (NovoSeven®) as a hemostatic agent. Dis Mon 2003; 49: 39-48.
12. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64.
13. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
14. Hoffman M. A cell-based model of haemostasis. Blood Rev 2003; 17: S1-S5.
15. Monroe DM, Hoffman M, Oliver JA et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
16. Rauch U, Bonderman D, Badimon J et al. Platelets become tissue factor positive during thrombus formation. Blood 1998; 92: 347a.
17. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin- activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
18. Cawthern KM, van't Veer C, Lock JB et al. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
19. Kjalke M, Ezban M, Monroe DM et al. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001; 114: 114-20.
20. Hoffman M, Monroe DM 3rd. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38: 6-9.
21. Lisman T, Adelmeijer J, Heijnen HF et al. Recombinant factor VIIa restores aggregation of alphaIIb-beta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103: 1720-7.
22. Gabriel DA, Li X, Monroe DM 3rd et al. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost 2004; 2: 1816-22.
23. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138-9.
24. ten Cate H, Bauer KA, Levi M et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-12.
25. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
26. Butenas S, Brummel KE, Bouchard BA et al. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1: 1158-60.
27. Butenas S, Brummel KE, Paradis SG et al. Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia. Arterioscler Thromb Vasc Biol 2003; 23: 123-9.
28. Lisman T, Mosnier LO, Lambert T et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99: 175-9.
29. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 531-9.
30. Hedner U, Glazer S, Pinkel K et al. Successful use of rFVIIa in a patient with severe haemophilia A subjected to synovectomy. Lancet 1988; ii: 1193.
31. Shapiro AD, Gilchrist GS, Keith Hoots WK et al. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
32. Lusher JM, Roberts HR, Davignon G et al. A randomized, double blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4: 790-8.
33. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
34. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
35. Laurian Y, Goudemand J, Negrier C et al. Use of recombinant activated factor VII as first line therapy for bleeding episodes in hemophiliacs with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998; 9: S155-S156.
36. Ingerslev J, Thykjaer H, Kudsk Jensen O et al. Home treatment with recombinant activated factor VII: results from one center. Blood Coagul Fibrinolysis 1998; 9: S107-10.
37. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
38. Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26(Suppl 1): 118-23.
39. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
40. Rodriguez-Merchan EC, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 2004; 10(Suppl. 2): 22-9.
41. Tagariello G, De Biasi E, Gajo GB et al. Recombinant FVIIa continuous infusion and total hip replacement in patient with hemophilia and high titer of inhibitors to FVIII: experiences of two cases. Haemophilia 2000; 6: 581-3.
42. Schulman S, Bech-Jensen M, Varon D et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 432-6.
43. Ludlam CA, Smith MP, Morfini M et al. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
44. Baudo F, Redaelli R, Caimi TM et al. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 2000; 99: 21-4.
45. Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
46. Mauser-Bunschoten EP, Goede-Bolder A, Wielenga JJ et al. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium. Neth J Med 1998; 53: 249-55.
47. Montoro JB, Altisent C, Pico M et al. Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. Haemophilia 1998; 4: 762-5.
48. Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD et al. The Recombinant Factor VIIa Data Collection Group. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors. Haemophilia 2002; 8: 649-56.
49. Kenet G, Lubetsky A, Luboshitz J et al. Treatment of inhibitor patients with rFVIIa: continuous infusion protocols as compared to a single, large dose. Haemophilia 2000; 6: 279a.
50. Schulman S, D'Oiron R, Martinowitz U et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998; 9: S97-S101.
51. Smith MP, Ludlam CA, Collins PW et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86: 949-53.
52. McPherson J, Sutcharitchan P, Lloyd J et al. Experience with continuous infusion of recombinant activated factor VII in the Asia-Pacific region. Blood Coagul Fibrinolysis 2000; 11: S31-S34.
53. Chuansumrit A, Isarangkura P, Angchaisuksiri P et al. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Haemophilia 2000; 6: 61-5.
54. Santagostino E, Morfini M, Rocino A et al. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
55. Ewenstein BM. Continuous infusion of recombinant factor VIIa: continue or not? Thromb Haemost 2001; 86: 942-4.
56. Kenet G, Lubetsky A, Luboshitz J et al. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven®). J Thromb Haemost 2003; 1: 450-5.
57. Shapiro A. Inhibitor treatment: state of the art. Dis Mon 2003; 49: 22-38.
58. Key NS, Nelsestuen GL. Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Sem Hematol 2004; 41: 51-4.
59. Sørensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
60. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Sem Hematol 2004; 41: 20-4.
61. Arkin S, Blei F, Fetten J et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255-9.
62. Von Depka M. NovoSeven: mode of action and use in acquired haemophilia. Intensive Care Med 2002; 28: S222-7.
63. Majundar G, Phillips JK, Lavallee H et al. Acquired hemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa. Blood Coagul Fibrinolysis 1993; 4: 1035-7.
64. Shafi T, Jeha MT, Black L et al. Severe acquired hemophilia A treated with recombinant factor VIIa. Br J Haematol 1997; 98: 910-2.
65. Maliekel K, Rana N, Green D. Recombinant factor VIIa in the management of a pseudotumor in acquired haemophilia. Haemophilia 1997; 3: 54-8.
66. Papadaki HA, Xylouri I, Valatas W et al. Severe acquired hemophilia A successfully treated with activated recombinant human factor VII. Ann Hematol 1998; 77: 123-5.
67. Liebman HA, Chediak J, Fink KI et al. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 200; 63: 109-13.
68. Franchini M, Girelli D, Olivieri O et al. Clinical heterogeneity of acquired hemophilia A: a description of 4 cases. Haematologica 2005; 90: ECR16.
69. Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 79: 1463-7.
70. Baudo F, de Cataldo F, Gaidano G. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica 2004; 88: 759-61.
71. Perry DJ. Factor VII deficiency. Blood Coagul Fibrinolyisis 2003; 14 (suppl. 1): S47-54.
72. Mariani G, Mannucci PM, Mazzucconi MG et al. Treatment of congenital factor VII deficiency with a new concentrate. Thromb Haemost 1978; 39: 675-82.
73. Dike GW, Griffiths D, Bidwell E et al. A factor VII concentrate for therapeutic use. Br J Haematol 1980; 45: 107-18.
74. Billio A, Pescosta N, Rosanelli C et al. Successful short term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency. Blood Coagul Fibrinolysis 1997; 8: 249-50.
75. Mariani G, Testa MG, Di Paolantonio T et al. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77:131-6.
76. Wong WY, Huang WC, Miller R et al. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial hemorrhage in severe neonatal FVII deficiency. Haemophilia 2000; 6: 50-4.
77. Weei-Yuarn H, Kruskall MS, Bauer KA et al. The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. Transfusion 2004; 44: 1562-6.
78. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
79. Ingerslev J, Knudsen L, Hvid I et al. Use of recombinant factor VIIa in surgery in factor VII deficient patients. Haemophilia 1997; 3: 215-8.
80. Tcheng WY, Donkin J, Konzal S et al. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency. Haemophilia 2004; 10: 295-8.
81. Mathijssen NC, Masereeuw R, Verbeek K et al. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. Br J Haematol 2004; 125: 494-9.
82. Laurian Y. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa? Pathophysiol Haemost Thromb 2002; 32: 37-40.
83. Goodnough LT. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol 2004; 41(suppl 1): 25-9.
84. Kristensen J, Killander A, Hippe E et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26(suppl 1): 159-64.
85. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000; 83: 634-5.
86. Gerotziafas GT, Zervas C, Gavrielidis G et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002; 69: 219-22.
87. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999; 82: 1778.
88. Poon MC, Demers C, Jobin F et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3.
89. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981-2.
90. Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis 2000;11(Suppl 1): S55-68.
91. Caglar K, Cetinkaya A, Aytac S et al. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003; 20: 435-8.
92. Chuansumrit A. Confirmation of high dose recombinant factor VIIa in treating patients with Glanzmann thrombasthenia. J Thromb Haemost 2003;1:396.
93. Chuansumrit A, Suwannuraks M, Sri-Udomporn N et al. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003;14: 187-90.
94. Poon MC, d'Oiron R, Hann I et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 2001; 38: 21-5.
95. Almeida A, Khair K, Hann I et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477-81.
96. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998; 80: 352.
97. Fressinaud E, Sigaud-Fiks M, Le Boterff C et al. Use of recombinant factor VIIa (NovoSeven®) for dental extraction in a patient affected by platelet-type (pseudo-) von Willebrand disease. Haemophilia 1998;4: XXIIIth Congress of the World Federation of Hemophilia (abstract).
98. Poon MC, Katsarou O, Huth-Kuehne A et al. Recombinant factor VIIa in congenital platelet bleeding disorders. American Society of Hematology 2000, 1-5 December, San Francisco. Blood; 96(suppl 1): 256a (abstract).
99. Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S69-74.
100. Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology 2004; 39: 592-8.
101. Bernstein DE, Jeffers L, Erhardtsen E et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113: 1930-7.
102. Jeffers L, Chalasani N, Balart L et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002; 123: 118-26.
103. Bosch J, Thabut D, Bendtsen F. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 1123-30.
104. Ejlersen E, Melsen T, Ingerslev J et al. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001, 10: 1081-5.
105. Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F et al. Recombinant activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clinical Gastroenterol Hepatol 2004; 2: 78-84.
106. O'Connell NM, Perry DJ, Hodgson AJ et al. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003; 43: 1711-6.
107. Shami VM, Caldwell SH, Hespendeide EE et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9: 138-43.
108. Kalicinski P, Kaminski A, Drewniak T et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999; 31: 378-9.
109. Hendriks HG, Meijer K, de Wolf JT et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001; 71: 402-5.
110. Meijer K, Hendriks HGD, de Wolf JTM et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 2003; 14: 169-74.
111. Planinsic RM, Testa G, Emre S et al. Safety and efficacy of single bolus dose of recombinant factor VIIa in patients undergoing orthotopic liver transplantation: a randomized multi-center study. Hepatology 2002: 36: 660A.
112. Grounds M. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Reviews 2003; 17: S11-S21.
113. Kenet G, Walden R, Eldad A et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
114. Martinowitz U, Holcomb JB, Pusateri AE et al. Intravenous rFVIIa administered for haemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001; 50: 721-9.
115. Mayo A, Misgav M, Kluger Y et al. Recombinant activated factor VII (Novoseven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang 2004, 87: 34-40.
116. Martinowitz U, Kenet G, Segal E et al. Recombinant activated factor VII for adjunctive haemorrhage control in adults. J Trauma 2001; 51: 431-9.
117. O'Neill PA, Bluth M, Gloster ES et al. Successful use of recombinant activated factor VII for trauma-associated haemorrhage in a patient without preexisting coagulopathy. J Trauma 2002; 52: 400-5.
118. Kamphuisen PW, van den Akker JM, Kaasjager KAH. Control of life-threatening pulmonary bleeding with activated recombinant factor VII. Am J Med 2002; 112: 332-3.
119. Svartholm E, Annerhagen V, Lanne T. Treatment of bleeding in severe necrotising pancreatitis with recombinant factor VIIa. Anesthesiology 2002; 96: 1528.
120. Aggarwal A, Catlett J, Alcorn K. The use of recombinant factor VIIa in the management of intractable bleeding in surgical and trauma patients. American Society of Hematology Presentation, 43rd Annual Meeting, Orlando; December 2001 [Abstract 3883].
121. Bouwmeester FW, Jonjhoff AR, Verheijen RHM et al. Successful treatment of life-threatening post partum haemorrhage with recombinant activated factor VII. Obstet Gynaecol 2003; 101: 1174-6.
122. Boehlen F, Morales MA, Fontana P et al. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. Br J Obstet Gynaecol 2004; 111: 284-7.
123. Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003; 82: 257-8.
124. Al Douri M, Shafi T, Al Khudairi D et al. Effect of the administration of recombinant activated factor VII (rFVIIa; Novoseven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S121-7.
125. Hendriks HGD, van der Maaten JMAA, de Wolf J et al. An effective treatment of severe intractable bleeding after heart valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001; 93: 287-9.
126. Karkouti K, Beattie WS, Wijeysundera DN et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005; 45: 26-34.
127. Zietkiewitcz M, Garlicki M, Domagala J et al. Successful use of rFVIIa to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg 2002; 123: 384-5.
128. Potapov EV, Pasic M, Bauer M et al. Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device. Ann Thorac Surg 2002; 74: 2182-3.
129. Friederich PW, Henny CP, Messelink EJ et al. The effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-5.
130. White B, McHale J, Ravi N et al. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999; 107: 677-8.
131. Vlot AJ, Ton E, Mackaay AJC et al. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med 2000; 108: 421-2.
132. Lodge P, Jonas S, Jaeck D et al. Recombinant factor VIIa (NovoSeven®) in partial hepatectomy: a randomized, placebo-controlled, double blind clinical trial. Presented at the American Association for the Study of Liver Diseases Annual Meeting, Boston, Nov 2002. Abstract 177.
133. Park P, Fewel ME, Garton HJ et al. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophiliac neurosurgical patients. Neurosurgery 2003: 53: 34-9.
134. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg 2001; 94: 1369-71.
135. Ciavarella N, Schiavoni M, Valenzano E et al. Use of recombinant factor VIIa in the treatment of two patients with type III von Willebrand's disease and an inhibitor against the von Willebrand factor. Haemostasis 1996; 26: 150-4.
136. Billon S, Niger CL, Escoffre-Barbe M et al. The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001; 12: 551-3.
137. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 1: 307-17.
138. Lawler P, White B, Pye S et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002; 8: 145-8.
139. Bern MM, Sahud M, Zhukov O et al. Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia 2005; 11: 20-5.
140. O'Connell NM. Factor XI deficiency. Sem Hematol 2004; 41: 76-81.
141. Waddington DP, McAuley FT, Hanley JP et al. The use of recombinant factor VIIa in a Jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. Br J Haematol 2002; 119: 286-8.
142. Mindikoglu AL, Anantharaju A, George M et al. Splenic embolization in a Jehovah's Witness: role of recombinant human factor VIIa. Hepatogastroenterology 2003; 50: 1697-9.
143. Virchis A, Hughes C, Berney S. Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia. Hematol J 2004; 5: 281-2.
144. Tanaka KA, Waly AA, Cooper WA et al. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003; 98: 1513-5.
145. Blatt J, Gold SH, Wiley JM et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28: 405-7.
146. de Fabritiis P, Dentamaro T, Picardi A et al. Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica 2004; 89: 243-5.
147. Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975-8.
148. Diness V, Lund-Hansen T, Hedner U. Effects of recombinant human FVIIa on warfarin-induced bleeding in rats. Thrombosis Res 1990; 59: 921-9.
149. Erhardtsen E, Nony P, Dechavanne M et al. The effect of recombinant factor VIIa (NovoSeven™) in healthy volunteers receiving acenocoumarol to an International Normalised Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9: 741-8.
150. Berntorp E, Stigendal L, Lethagen S et al. NovoSeven in warfarin-treated patients. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S113-5.
151. Deveras RAE, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant factor VIIa concentrate. Ann Intern Med 2002; 137: 884-8.
152. Sorensen B, Johansen P, Nielsen GL et al. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14: 469-77.
153. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit 2002; 8: CS98-100.
154. Udvardy M, Telek B, Mezey G et al. Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog alpha, NovoSeven) in a patient with a prosthetic aortic valve and two malignancies (chronic lymphoid leukemia and lung cancer). Blood Coagul Fibrinolysis 2004; 15: 265-7.
155. Rice KM, Savidge GF. Novoseven® (recombinant factor VIIa) in central nervous system bleeds. Haemostasis 1996; 26(Suppl 1): 131-4.
156. Tobias JD. Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children. Anesthesiology 2002; 96: 1522-5.
157. Mayer SA, Brun NC, Broderick J et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2004 Nov 29; [Epub ahead of print].
158. Greisen G, Andreasen AB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis 2003; 14: 117-20.
159. Bianchi A, Jackson D, Maitz P et al. Treatment of bleeding with recombinant factor VIIa in a patient with extensive burns. Thromb Haemost 2004; 91: 203-4.
160. Revesz T, Arets B, Bierings M et al. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost 1998; 80: 353.
161. Hay CRM. Thrombosis and recombinant factor VIIa. J Thromb Haemost 2004; 2: 1698-9.
162. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
163. Roberts HS, Monroe III DM, Hoffman M. Safety profile of recombinant factor VIIa. Sem Hematol 2004; 1(Suppl 1): 101-8.
164. Guillet B, Pinganaud C, Proulle V et al. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Thromb Haemost 2002; 88: 698-9.
165. Peerlink K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-6.
166. Bui JD, Despotis GD, Trulock EP et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002; 124: 852-4.
167. O'Connell NM. Factor XI deficiency: from molecular genetics to clinical management. Blood Coagul Fibrinolysis 2003; 14(Suppl. 1): S59-64.
168. Pickard JD, Kirkpatrick PJ, Melsen T et al. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S117-20.
169. d'Oiron R, Menart C, Trzeciak MC et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-7.
170. Laffan M, O'Connell NM, Perry DJ et al. Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagul Fibrinolysis 2003; 14(Suppl 1): S35-8.
171. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 95: S13-17.
172. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.